Cover Image
市場調查報告書

PharmaPoint:大腸癌 - 中國的醫藥品的預測與市場分析

PharmaPoint: Colorectal Cancer - China Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 321681
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:大腸癌 - 中國的醫藥品的預測與市場分析 PharmaPoint: Colorectal Cancer - China Drug Forecast and Market Analysis to 2023
出版日期: 2014年11月28日 內容資訊: 英文 135 Pages
簡介

大腸癌(結腸直腸癌:CRC)是全球癌症死亡原因第二位。也是確診癌症患者最多的第三名,對醫療制度而言已經是一大負擔。

本報告提供中國的大腸癌(結腸直腸癌:CRC)治療藥市場相關調查分析,提供您疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 臨床階段
  • 症狀

第4章 疾病的管理

  • 診斷和治療概要
  • 中國

第5章 競爭評估

  • 概要
  • 產品簡介:領導品牌

第6章 未滿足需求和機會

  • 概要
  • 可實質提升轉移性患者整體生存率的治療
  • KRAS·BRAF變異陽性患者的標靶治療
  • 可切除的高風險患者之有效新佐劑/佐劑療法
  • 化療阻力性患者可接受的後期治療

第7章 開發平台評估

  • 概要
  • 開發初期階段的潛力療法

第8章 市場預測

  • 中國

第9章 附錄

圖表

目錄
Product Code: GDHC260CFR

GlobalData has released its new PharmaPoint Country Evaluation report, "PharmaPoint: Colorectal Cancer - China Drug Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

GlobalData calculates branded CRC therapeutics to have generated $259m in sales in China in 2013. GlobalData expects growth of the Chinese CRC market to be driven by increasing incidence of the disease in urban populations, increased numbers of people covered by private health insurance, increased access to branded biologicals, and uptake of pipeline agents. However, growth will be stymied by patent expiration of Avastin, the market-leading drug in the Chinese CRC market. GlobalData anticipates the launch of bevacizumab biosimilars in China from 2019 onwards.

Scope

  • Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in China from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the China CRC market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for CRC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in China.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Clinical Staging
  • 3.3. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Screening and Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. China
    • 4.2.1. Screening and Diagnosis
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands
    • 5.2.1. Avastin (Bevacizumab)
    • 5.2.2. Erbitux (Cetuximab)
    • 5.2.3. Vectibix (Panitumumab)
    • 5.2.4. Stivarga (Regorafenib)
    • 5.2.5. Zaltrap (Ziv-Aflibrcept)
    • 5.2.6. Lonsurf (TAS-102)
    • 5.2.7. Xeloda (Capecitabine)

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Approaches in Early-Stage Development
    • 7.2.1. Anti-Angiopoietin-2 Inhibitors
    • 7.2.2. Strategies for BRAF Mutation-Positive Disease
    • 7.2.3. Strategies for KRAS-Mutation Positive Disease
    • 7.2.4. Immune Checkpoint Inhibitors

8. Market Outlook

  • 8.1. China
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers - Global Issues
    • 8.1.4. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Colorectal Cancer Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiration Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Average Body Weight and Surface Area
    • 9.4.7. Individual Drug Assumptions
    • 9.4.8. Generic Erosion
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: TNM and Staging Classification System for CRC
  • Table 2: Symptoms of Colorectal Cancer
  • Table 3: Treatment Guidelines for CRC
  • Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the US Markets, 2013
  • Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the US Markets, 2013
  • Table 6: Country Profile - China
  • Table 7: Leading Treatments for CRC, 2014
  • Table 8: Product Profile - Avastin
  • Table 9: Avastin SWOT Analysis, 2014
  • Table 10: Product Profile - Erbitux
  • Table 11: Erbitux SWOT Analysis, 2014
  • Table 12: Product Profile - Vectibix
  • Table 13: Vectibix SWOT Analysis, 2014
  • Table 14: Product Profile - Stivarga
  • Table 15: Stivarga SWOT Analysis, 2014
  • Table 16: Product Profile - Zaltrap
  • Table 17: Zaltrap SWOT Analysis, 2014
  • Table 18: Product Profile - Lonsurf
  • Table 19: Lonsurf SWOT Analysis, 2014
  • Table 20: Product Profile - Xeloda
  • Table 21: Unmet Need and Opportunity in CRC
  • Table 22: Anti-Angiopoietin-2 Inhibitors in Development
  • Table 23: Early-stage Strategies for BRAF Mutation-Positive CRC
  • Table 24: Early-stage Strategies for KRAS Mutation-Positive CRC
  • Table 25: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC
  • Table 26: Sales Forecasts ($m) for Colorectal Cancer in China, 2013-2023
  • Table 27: Key Events Impacting Sales for CRC in China, 2014
  • Table 28: CRC Market Drivers and Barriers, 2014
  • Table 29: China CRC Market - Drivers and Barriers, 2014
  • Table 30: Key Launch Dates
  • Table 31: Key Patent Expiries
  • Table 32: Average Body Weight and Surface Area
  • Table 33: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Sales for Colorectal Cancer in China by Drug Class, 2013-2023
Back to Top